Schmidt, NM;
Wing, PAC;
McKeating, JA;
Maini, MK;
(2020)
Cholesterol-modifying drugs in COVID-19.
Oxford Open Immunology
, 1
(1)
, Article iqaa001. 10.1093/oxfimm/iqaa001.
Preview |
Text
iqaa001.pdf - Published Version Download (300kB) | Preview |
Abstract
Infection with severe acute respiratory syndrom coronavirus 2 (SARS-CoV-2) is more likely to lead to poor outcomes in the elderly and those with cardiovascular disease, obesity or metabolic syndrome. Here, we consider mechanisms by which dyslipidaemia and the use of cholesterol-modifying drugs could influence the virus–host relationship. Cholesterol is essential for the assembly, replication and infectivity of enveloped virus particles; we highlight several cholesterol-modifying drugs with the potential to alter the SARS-CoV-2 life cycle that could be tested in in vitro and in vivo models. Although cholesterol is an essential component of immune cell membranes, excess levels can dysregulate protective immunity and promote exaggerated pulmonary and systemic inflammatory responses. Statins block the production of multiple sterols, oxysterols and isoprenoids, resulting in a pleiotropic range of context-dependent effects on virus infectivity, immunity and inflammation. We highlight antiviral, immunomodulatory and anti-inflammatory effects of cholesterol-modifying drugs that merit further consideration in the management of SARS-CoV-2 infection.
| Type: | Article |
|---|---|
| Title: | Cholesterol-modifying drugs in COVID-19 |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1093/oxfimm/iqaa001 |
| Publisher version: | https://doi.org/10.1093/oxfimm/iqaa001 |
| Language: | English |
| Additional information: | © The Author(s) 2020. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | COVID-19, SARS-CoV-2, viral immunology, T-cells, cholesterol-modifying drugs, inflammation, statins, dyslipidemia |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10106773 |
Loading...
Loading...Loading...Loading...Archive Staff Only
 |
View Item |
